A Phase 1b/2 Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer.

Brief description of study

You can participate in this study if you are diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to standard-of care chemotherapy in participants with metastatic colorectal cancer (Ph2 cohorts), and to assess the recommended phase 2 combination dose of amivantamab when added to standard-of care chemotherapy (Ph1b cohorts).

Clinical Study Identifier: s22-00147
ClinicalTrials.gov Identifier: NCT05379595
Principal Investigator: Paul E. Oberstein.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.